Contact
searchSearch
HMP Global
Login

News

open and spilled bottle of pills
News
Beta-Blockers Ineffective for Treating Psychological Symptoms of Anxiety
04/24/2025
Maria Mantas
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no...
04/24/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
strand of DNA
News
Genetic Liability for Schizophrenia May Affect Traumatic Brain Injury Associations
04/21/2025
Jolynn Tumolo
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for...
04/21/2025
Psych Congress Network
injection for schizophrenia treatment
News
Antipsychotic Sedation Peaks in First 2 Weeks, Emphasizing Importance of Early Monitoring
04/21/2025
Maria Mantas
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized...
04/21/2025
Psych Congress Network
older woman with depression
News
Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds
04/16/2025
Maria Mantas
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found...
04/16/2025
Psych Congress Network
Viloxazine Molecule
News
Viloxazine ER: A Nonstimulant in ADHD Treatment
04/14/2025
Viloxazine ER is a nonstimulant medication for ADHD that has a unique mechanism of action compared to traditional stimulant medications, broadening the therapeutic landscape.
Viloxazine ER is a nonstimulant medication for ADHD that has a unique mechanism of action compared to traditional stimulant medications, broadening the therapeutic landscape.
Viloxazine ER is a nonstimulant...
04/14/2025
Psych Congress Network
an assortment of pills spilled out on a yellow table
News
Inpatient Addiction Consultation Service Promotes MOUD in Patients with OUD
04/14/2025
Jolynn Tumolo
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical...
04/14/2025
Psych Congress Network
Hormonal Contraceptive Pills
News
Post Partum Hormonal Contraception Use Linked with Heightened Depression Risk
04/09/2025
Jolynn Tumolo
The initiation of hormonal contraception post partum was associated with an immediate increase in depression risk in first-time mothers in Denmark, according to a study published in JAMA Network Open.
The initiation of hormonal contraception post partum was associated with an immediate increase in depression risk in first-time mothers in Denmark, according to a study published in JAMA Network Open.
The initiation of hormonal...
04/09/2025
Psych Congress Network
A woman taking a pill
News
New Study Finds Quetiapine More Effective Than Lithium in Reducing Treatment-Resistant Depression Symptoms
04/09/2025
Maria Mantas
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more...
04/09/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use